Quantum Biopharma Stock Current Liabilities
| QNTM Stock | 3.84 0.17 4.24% |
Quantum BioPharma fundamentals help investors to digest information that contributes to Quantum BioPharma's financial success or failures. It also enables traders to predict the movement of Quantum Stock. The fundamental analysis module provides a way to measure Quantum BioPharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Quantum BioPharma stock.
Quantum |
Quantum BioPharma Company Current Liabilities Analysis
Quantum BioPharma's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Quantum BioPharma has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Quantum Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Quantum BioPharma's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Quantum BioPharma could also be used in its relative valuation, which is a method of valuing Quantum BioPharma by comparing valuation metrics of similar companies.Quantum BioPharma is currently under evaluation in current liabilities category among its peers.
Quantum Fundamentals
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.36 | ||||
| Current Valuation | 3.47 M | ||||
| Shares Outstanding | 1.55 M | ||||
| Shares Owned By Insiders | 14.10 % | ||||
| Shares Owned By Institutions | 1.54 % | ||||
| Number Of Shares Shorted | 15.23 K | ||||
| Price To Book | 0.55 X | ||||
| Price To Sales | 91.86 X | ||||
| EBITDA | (10.06 M) | ||||
| Net Income | (17.9 M) | ||||
| Total Debt | 300.55 K | ||||
| Book Value Per Share | 15.02 X | ||||
| Cash Flow From Operations | (10.83 M) | ||||
| Short Ratio | 0.22 X | ||||
| Earnings Per Share | (13.00) X | ||||
| Target Price | 169.0 | ||||
| Number Of Employees | 10 | ||||
| Beta | 0.85 | ||||
| Market Capitalization | 6.17 M | ||||
| Total Asset | 17.47 M | ||||
| Retained Earnings | (157.91 M) | ||||
| Working Capital | 6.52 M | ||||
| Net Asset | 17.47 M |
About Quantum BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Quantum BioPharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Quantum BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Quantum BioPharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Quantum BioPharma Piotroski F Score and Quantum BioPharma Altman Z Score analysis. To learn how to invest in Quantum Stock, please use our How to Invest in Quantum BioPharma guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Quantum BioPharma. If investors know Quantum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Quantum BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Quantum BioPharma is measured differently than its book value, which is the value of Quantum that is recorded on the company's balance sheet. Investors also form their own opinion of Quantum BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Quantum BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Quantum BioPharma's market value can be influenced by many factors that don't directly affect Quantum BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Quantum BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Quantum BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Quantum BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.